ArticleDiscover oncology2025
Real-time survival assessment in breast cancer with liver metastasis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: Real-time survival assessment in breast cancer with liver metastasis.Discover oncology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe heterogeneity in outcomes of breast cancer liver metastasis (BCLM) complicates prognosis assessment. This study conducted conditional survival (CS) analysis and develop a CS-nomogram model for BCLM using SEER database data, providing individualized and adaptive prognostic predictions.
methodsData were extracted from the SEER 18 database, encompassing clinical records of BCLM patients diagnosed between 2010 and 2021. CS was calculated using the formula CS(t∣s) = S(t + s)/S(s), allowing for the dynamic assessment of survival probabilities. Annual hazard rate (AHR) analysis was performed to evaluate the risk of mortality at specific time intervals. A two-stage feature selection process was used to identify prognostic factors. We then developed a CS-nomogram, validated through calibration curves, time-dependent receiver operating characteristic curve (ROC) analysis, and decision curve analysis (DCA).
resultsThe study cohort comprised 4,702 BCLM patients. The CS analysis and AHR analysis demonstrated that survival probabilities improved progressively for patients who survived beyond the high-risk period, particularly during the first year post-diagnosis. The CS-nomogram, developed using Cox regression, incorporated 14 variables, including patient characteristics, tumor features, and treatment information. It effectively predicted overall survival and CS at 3, 5, and 10 years. The model's clinical utility was confirmed through calibrations, ROC with area under the curve values, and DCA, offering valuable insights for individualized treatment decisions.
conclusionBy incorporating CS analysis, this study provided a dynamic, adaptable approach to predict prognosis for BCLMs. The CS-nomogram model transformed survival probabilities into a continuously adjustable process, supporting more precise clinical decision-making and offering hope to patients with a historically poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.